131 related articles for article (PubMed ID: 15389471)
21. Gynecologic Cancer InterGroup (GCIG) consensus review for uterine serous carcinoma.
Sagae S; Susumu N; Viswanathan AN; Aoki D; Backes FJ; Provencher DM; Vaughan M; Creutzberg CL; Kurzeder C; Kristensen G; Lee C; Kurtz JE; Glasspool RM; Small W
Int J Gynecol Cancer; 2014 Nov; 24(9 Suppl 3):S83-9. PubMed ID: 25341586
[TBL] [Abstract][Full Text] [Related]
22. The management of serous papillary uterine cancer.
Schwartz PE
Curr Opin Oncol; 2006 Sep; 18(5):494-9. PubMed ID: 16894299
[TBL] [Abstract][Full Text] [Related]
23. Role of systematic lymphadenectomy and adjuvant therapy in stage I uterine papillary serous carcinoma.
Thomas MB; Mariani A; Cliby WA; Keeney GA; Podratz KC; Dowdy SC
Gynecol Oncol; 2007 Nov; 107(2):186-9. PubMed ID: 17688926
[TBL] [Abstract][Full Text] [Related]
24. Adjuvant therapy for patients with stage I papillary serous endometrial cancer.
Alobaid A; Bruchim I; Verkooijen H; Gauthier P; Petignat P
Eur J Surg Oncol; 2006 Apr; 32(3):358-62. PubMed ID: 16414233
[TBL] [Abstract][Full Text] [Related]
25. Utility of pre-operative serum CA-125 in the management of uterine papillary serous carcinoma.
Olawaiye AB; Rauh-Hain JA; Withiam-Leitch M; Rueda B; Goodman A; del Carmen MG
Gynecol Oncol; 2008 Sep; 110(3):293-8. PubMed ID: 18644620
[TBL] [Abstract][Full Text] [Related]
26. Prognostic factors and treatment-related outcome in patients with uterine papillary serous carcinoma.
Sagr ER; Denschlag D; Kerim-Dikeni A; Stanimir G; Gitsch G; Gilbert L
Anticancer Res; 2007; 27(2):1213-7. PubMed ID: 17465265
[TBL] [Abstract][Full Text] [Related]
27. Minimal uterine serous carcinoma: current concepts in diagnosis and prognosis.
Rabban JT; Zaloudek CJ
Pathology; 2007 Feb; 39(1):125-33. PubMed ID: 17365828
[TBL] [Abstract][Full Text] [Related]
28. Synchronous ovarian granulosa cell tumor and uterine serous carcinoma: a rare association of a high-risk endometrial cancer with anestrogenic ovarian tumor.
Rabban JT; Gupta D; Zaloudek CJ; Chen LM
Gynecol Oncol; 2006 Dec; 103(3):1164-8. PubMed ID: 17034837
[TBL] [Abstract][Full Text] [Related]
29. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
Silva EG; Gershenson DM; Malpica A; Deavers M
Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
[TBL] [Abstract][Full Text] [Related]
30. Differential expression of WT-1 in serous carcinomas in the peritoneum with or without associated serous carcinoma in endometrial polyps.
Euscher ED; Malpica A; Deavers MT; Silva EG
Am J Surg Pathol; 2005 Aug; 29(8):1074-8. PubMed ID: 16006803
[TBL] [Abstract][Full Text] [Related]
31. Clinical significance of Her-2/neu overexpression in uterine serous carcinoma.
Díaz-Montes TP; Ji H; Smith Sehdev AE; Zahurak ML; Kurman RJ; Armstrong DK; Bristow RE
Gynecol Oncol; 2006 Jan; 100(1):139-44. PubMed ID: 16182348
[TBL] [Abstract][Full Text] [Related]
32. MicroRNA expression profiles in serous ovarian carcinoma.
Nam EJ; Yoon H; Kim SW; Kim H; Kim YT; Kim JH; Kim JW; Kim S
Clin Cancer Res; 2008 May; 14(9):2690-5. PubMed ID: 18451233
[TBL] [Abstract][Full Text] [Related]
33. Clinical aspects of uterine papillary serous carcinoma.
Hamilton CA; Kapp DS; Chan JK
Curr Opin Obstet Gynecol; 2008 Feb; 20(1):26-33. PubMed ID: 18197002
[TBL] [Abstract][Full Text] [Related]
34. Role of cytoreduction in stage III and IV uterine papillary serous carcinoma.
Thomas MB; Mariani A; Cliby WA; Keeney GL; Podratz KC; Dowdy SC
Gynecol Oncol; 2007 Nov; 107(2):190-3. PubMed ID: 17825394
[TBL] [Abstract][Full Text] [Related]
35. What Has Changed in the Management of Uterine Serous Carcinomas? Two Decades of Experience.
Liontos M; Svarna A; Theofanakis C; Fiste O; Andrikopoulou A; Kaparelou M; Koutsoukos K; Thomakos N; Haidopoulos D; Rodolakis A; Dimopoulos MA; Zagouri F
Curr Oncol; 2021 Nov; 28(6):4862-4873. PubMed ID: 34898589
[TBL] [Abstract][Full Text] [Related]
36. [Clinical and pathologic analysis of 33 cases of uterine papillary serous carcinoma].
Ren YL; Wang HY; Shen L; Yang WT
Zhonghua Fu Chan Ke Za Zhi; 2006 Dec; 41(12):817-21. PubMed ID: 17327111
[TBL] [Abstract][Full Text] [Related]
37. Microarray analysis of endometrial carcinomas and mixed mullerian tumors reveals distinct gene expression profiles associated with different histologic types of uterine cancer.
Maxwell GL; Chandramouli GV; Dainty L; Litzi TJ; Berchuck A; Barrett JC; Risinger JI
Clin Cancer Res; 2005 Jun; 11(11):4056-66. PubMed ID: 15930340
[TBL] [Abstract][Full Text] [Related]
38. Grading of serous ovarian carcinoma: further evidence of a lack of agreement between conventional grading systems.
Singh N; Ayhan A; Menon U; Chin Aleong JA; Faruqi AZ; Gayther SA; Jacobs IJ
Histopathology; 2008 Feb; 52(3):393-5. PubMed ID: 18081817
[No Abstract] [Full Text] [Related]
39. Prognosis of uterine corpus cancer after tamoxifen treatment for breast cancer.
Hoogendoorn WE; Hollema H; van Boven HH; Bergman E; de Leeuw-Mantel G; Platteel I; Fles R; Nederlof PM; Mourits MJ; van Leeuwen FE;
Breast Cancer Res Treat; 2008 Nov; 112(1):99-108. PubMed ID: 18064567
[TBL] [Abstract][Full Text] [Related]
40. Primary peritoneal serous papillary carcinoma: clinical and laboratory characteristics.
Iavazzo C; Vorgias G; Katsoulis M; Kalinoglou N; Dertimas V; Akrivos T
Arch Gynecol Obstet; 2008 Jul; 278(1):53-6. PubMed ID: 18488238
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]